HOME >> MEDICINE >> NEWS
Hepatotoxicity and statins

Statins appear to be safe for people with fatty liver disease who could benefit from their cholesterol-lowering capabilities, concludes a review paper published in the April 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., the journal is available online via Wiley InterScience at www.interscience.wiley.com/journal/hepatology.

Statins are a class of drugs that lower cholesterol levels by inhibiting the liver's production of cholesterol. They have been shown to decrease the risk of artherosclerosis and related diseases. In the United States, doctors write millions of prescriptions for statins each year. However, commonly, patients on statins have elevations of liver enzymes. Current statin product packaging recommends monitoring patients' liver values over the course of their usage. This recommendation may concern physicians whose patients also have known liver conditions, including elevated, though asymptomatic, liver enzymes.

Naga Chalasani, M.D., of Indiana University School of Medicine, thoroughly examined the literature related to statin hepatotoxicity to better understand statins' effects on patients. Statins, especially in increasing doses, have been associated with asymptomatic elevation of aminotransferases, though this occurs in fewer than three percent of statin users. Notably, this outcome has also occurred with similar frequency in placebo-treated patients in clinical trials. This "raises the possibility that hyperlipidemic patients may have spontaneous fluctuations in transaminases whether or not they receive statins," Chalasani suggests. Still, there have been rare reports of significant liver injury associated with statins.

Statins are not recommended for patients with active liver disease, though the recommendations for those with nonalcoholic fatty liver d
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
25-Mar-2005


Page: 1 2 3

Related medicine news :

1. Jefferson scientists help explain statins effects in Alzheimers disease
2. Jefferson scientists uncover new evidence to help explain statins effects in Alzheimers disease
3. CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome
4. OTC statins: A bad decision for public health
5. ESC highlights need for screening and global risk management as statins move over the counter in UK
6. ACP guidelines: Many diabetics should be taking statins
7. Patients should be allowed to pay for statins
8. Use of statins may prevent breast cancer, say University of Pittsburgh researchers
9. Genetic bar codes predict effect of statins
10. Stopping statins may cause rebound that triples risk of death

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hepatotoxicity and statins

(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
Cached News: